Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Publications

Animal Models of the Neuromuscular Junction, Vitally Informative for Understanding Function and the Molecular Mechanisms of Congenital Myasthenic Syndromes

Webster R., (2018), International Journal of Molecular Sciences, 19, 1326 - 1326

Serological and experimental studies in different forms of myasthenia gravis

Vincent A. et al, (2018), Annals of the New York Academy of Sciences, 1413, 143 - 153

Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient

Saxena A. et al, (2017), Scientific Reports, 7

Multiple roles of integrin-α3 at the neuromuscular junction

Ross JA. et al, (2017), Journal of Cell Science, 130, 1772 - 1784

Fast-channel congenital myasthenic syndrome with a novel acetylcholine receptor mutation at the α-ε subunit interface

Webster R. et al, (2014), Neuromuscular Disorders, 24, 143 - 147

A mouse model of the slow channel myasthenic syndrome: Neuromuscular physiology and effects of ephedrine treatment

Webster RG. et al, (2013), Experimental Neurology, 248, 286 - 298

Mutations in GFPT1 that underlie limb-girdle congenital myasthenic syndrome result in reduced cell-surface expression of muscle AChR

Zoltowska K. et al, (2013), Human Molecular Genetics, 22, 2905 - 2913

Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol

Finlayson S. et al, (2013), Muscle & Nerve, 47, 279 - 282

FAST CHANNEL CONGENITAL MYASTHENIA: REVIEW OF 12 CASES AND TREATMENT CHALLENGES

Finlayson S. et al, (2012), Journal of Neurology, Neurosurgery & Psychiatry, 83, A23.1 - A23

Presence and Pathogenic Relevance of Antibodies to Clustered Acetylcholine Receptor in Ocular and Generalized Myasthenia Gravis

Jacob S. et al, (2012), Archives of Neurology, 69

A novel congenital myasthenic syndrome due to decreased acetylcholine receptor ion-channel conductance

Webster R. et al, (2012), Brain, 135, 1070 - 1080

Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects

Viegas S. et al, (2012), Experimental Neurology, 234, 506 - 512

A novel congenital myasthenic syndrome due to decreased acetylcholine receptor ion-channel conductance

Webster R. et al, (2012), Brain, 135, 1070 - 1080

P23 Fluorescent receptors to light up the neuromuscular junction

Cossins J. et al, (2011), Neuromuscular Disorders, 21, S12 - S13

P33 Impaired neurotransmission in a mouse model of the slow channel congenital myasthenic syndrome is improved by the sympathomimetic drug ephedrine

Webster R. et al, (2011), Neuromuscular Disorders, 21, S15 - S15

Muscle Dysfunction Caused by a KATP Channel Mutation in Neonatal Diabetes Is Neuronal in Origin

Clark RH. et al, (2010), Science, 329, 458 - 461

PATHOGENIC MECHANISMS UNDERLYING MYASTHENIA GRAVIS ASSOCIATED WITH MUSK ANTIBODIES

Viegas S. et al, (2009), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 80

Congenital Myasthenic Syndromes and the Formation of the Neuromuscular Junction

Beeson D. et al, (2008), Annals of the New York Academy of Sciences, 1132, 99 - 103

CHRND mutation causes a congenital myasthenic syndrome by impairing co-clustering of the acetylcholine receptor with rapsyn

Muller JS., (2006), Brain, 129, 2784 - 2793

Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels

Webster RG. et al, (2005), British Journal of Pharmacology, 146, 1027 - 1039

Load More

Include forthcoming?